Analysis of the safety of dinutuximab β for the treatment of neuroblastoma
10.13406/j.cnki.cyxb.003814
- VernacularTitle:达妥昔单抗β治疗神经母细胞瘤的安全性分析
- Author:
Anle SHEN
1
;
Yali HAN
;
Liting YU
;
An'an ZHANG
;
Jie ZHAO
;
Qiushi YANG
;
Haonan LI
;
Zhiling LI
;
Yijin GAO
Author Information
1. 上海交通大学医学院附属上海儿童医学中心药剂科,上海 200127
- Keywords:
dinutuximab β;
neuroblastoma;
adverse reaction
- From:
Journal of Chongqing Medical University
2025;50(8):1042-1046
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical characteristics of adverse reactions caused by dinutuximab β for the treatment of neuro-blastoma(NB)in China and to provide safety evidence for the rational use of dinutuximab β in clinical practice.Methods:Clinical data were retrospectively collected from 16 pediatric patients with NB who had been treated with dinutuximab β at Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine from January 2022 to November 2023,and the adverse reactions caused by dinutuximab β were summarized and analyzed.Results:The male-to-female ratio was 5:3 among the 16 children with NB.The retroperitoneum was the main initial site of involvement,accounting for 75%.Thirteen(81.25%)patients had high-risk NB.The adverse reactions caused by dinutuximab β mainly included decreased hemoglobin,fever,vomiting,and diarrhea.The inci-dence of adverse reactions was highest in the first course of treatment,and the median time of adverse reactions was 2-5 days.Conclu-sion:Targeted monitoring should be carried out at an early stage during dinutuximab β administration.Adverse reactions should be de-tected and managed early to ensure the safety of medication for children.
